AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Phase 2
Terminated
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Biological: SalineBiological: MEDI8968
- First Posted Date
- 2013-04-24
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 224
- Registration Number
- NCT01838499
- Locations
- 🇺🇸
Research Site, Norfolk, Virginia, United States
Gefitinib Usage and Outcomes in Routine Treatment
Completed
- Conditions
- Lung Cancer
- First Posted Date
- 2013-03-27
- Last Posted Date
- 2014-01-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 157
- Registration Number
- NCT01818947
- Locations
- 🇬🇧
York District Hospital, York, United Kingdom
🇬🇧Royal Marsden Hospital, London, United Kingdom
🇬🇧Harrogate District Hospital, Harrogate, United Kingdom
To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses AZD8848 in Healthy Subjects
Phase 1
Completed
- Conditions
- Tolerability,Healthy SubjectsSafety,
- Interventions
- Drug: Placebo to match AZD8848
- First Posted Date
- 2013-03-27
- Last Posted Date
- 2015-08-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT01818869
- Locations
- 🇬🇧
Research Site, London, United Kingdom
To Assess the Safety, Tolerability, and Pharmacokinetics of AZD7624 in Healthy Volunteers and COPD Patients
- First Posted Date
- 2013-03-26
- Last Posted Date
- 2016-03-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 52
- Registration Number
- NCT01817855
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)
Completed
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2013-03-25
- Last Posted Date
- 2020-07-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2948
- Registration Number
- NCT01817569
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
The Risk of Uncomplicated Peptic Ulcer in a Cohort of Secondary Prevention Aspirin Users
Completed
- Conditions
- Uncomplicated Peptic Ulcer
- First Posted Date
- 2013-03-20
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 39000
- Registration Number
- NCT01814943
- Locations
- 🇪🇸
Research Site, Madrid, Spain
Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 23
- Registration Number
- NCT01813474
- Locations
- 🇯🇵
Research Site, Sapporo-shi, Japan
Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV
- Interventions
- First Posted Date
- 2013-03-12
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 55
- Registration Number
- NCT01809210
- Locations
- 🇬🇧
Research Site, Newcastle upon Tyne, United Kingdom
AZD9291 First Time In Patients Ascending Dose Study
Phase 1
Completed
- Conditions
- Advanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2013-03-01
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 603
- Registration Number
- NCT01802632
- Locations
- 🇬🇧
Research Site, Newcastle upon Tyne, United Kingdom
A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients
Phase 1
Completed
- Conditions
- Mild-to-moderate Alzheimer's Disease PatientsHealthy Elderly Volunteers
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2014-04-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 47
- Registration Number
- NCT01795339
- Locations
- 🇺🇸
Research Site, Glendale, California, United States